LPC
SRPT icon

Lion Point Capital’s Sarepta Therapeutics SRPT Stock Holding History

Lion Point Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$512K Hold
28,500
– – 2.45% 16
2026
Q1 		$620K Hold
28,500
– – 3.71% 10
2025
Q4 		$613K Buy
+28,500
New +$601K 3.17% 13

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Lion Point Capital's SRPT Position: Q2 2026 in Review

Lion Point Capital held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 28,500 shares worth $512K. The position accounts for 2.45% of the portfolio, ranked #16.

Lion Point Capital first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $620K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Lion Point Capital held 28,500 shares of Sarepta Therapeutics worth $512K as of Q2 2026.
  • Lion Point Capital left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up 2.45% of Lion Point Capital's portfolio in Q2 2026, its #16 holding.
  • Lion Point Capital first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Lion Point Capital's Sarepta Therapeutics position peaked at $620K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Lion Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.